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eply
he letter from Drs. Amorim and Doenst regarding an interpre-
ation of the data presented in our recent study (1) underscores the
mmense complexity of discerning the interplay between the
etabolic syndrome, coronary artery disease (CAD), diabetes, and
eart failure.
Drs. Amorim and Doenst rightly point out that the existence of
ardiac insulin resistance (cIR) in diabetes is still a matter of debate
nd that attributing the alterations in mitochondrial metabolism of
almitoyl-L-carnitine and glutamate that we observed in the
iabetic human hearts to cIR is questionable. We agree with this
tatement and wish to emphasize that this interpretation of the
ata was one of several put forth, along with the possibility that
iabetic hearts may not be responding appropriately to nutritional
tatus and substrate availability, that key mitochondrial enzymes in
he metabolic pathway for these substrates may be defective, or
oth. It also should be pointed out that in those studies that have
eported cIR, the question of when cIR develops during the course
f metabolic syndrome or diabetes also seems to be unresolved.
lthough many studies suggest that cIR is a strong predictor of the
evelopment of heart failure (2,3), other studies have shown that
eart failure can cause insulin resistance (4,5), thereby clouding the
ause-and-effect relationship between the two. With respect to our
tudy, we believe that although it is possible the nondiabetic
atients have cIR, the additional stress of overt diabetes has pushed
he diabetic hearts closer to a phenotype resembling that of heart
ailure (i.e., reduced fatty acid oxidative capacity and oxidative
tress). In any case, because these samples were obtained from
atients in a fasted state, measurement of insulin signaling proteins
n the heart samples would be of indeterminate value.
We also concur that the altered respiratory capacity seen in the
iabetic human heart tissue is not the result of a defect of
itochondrial complex I, but instead believe it to be the result of
pecific defects in the mitochondrial enzymes responsible for the
xidation of these substrates. Recent studies in animal models of
eart failure have shown defects that are strikingly similar (6,7),
ending further support to the proposition that the hearts of the
iabetic patients with CAD have a metabolic phenotype that is
loser to heart failure than nondiabetic, age-matched individuals
ith CAD alone.
Finally, because these data were generated in mitochondrial
reparations from atrial tissue and not ventricular tissue, it is
oubtful that ischemia concomitant to CAD is playing a role,
lthough it cannot be completely ruled out.
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tatins in Acute Coronary
yndromes and Genetic Insight
he report of Gibson et al. (1) addresses the issue of whether
ntensive statin therapy (atorvastatin 80 mg/day) leads to a greater
eduction in major adverse cardiac events (MACE) among patients
ndergoing percutaneous coronary intervention (PCI) for acute
oronary syndrome, compared with patients randomized to mod-
rate statin therapy (pravastatin 40 mg/day). Intensive statin
herapy reduced MACE and target vessel revascularization signif-
cantly more than standard statin therapy, and the authors noted
hat the effect was independent of low-density lipoprotein choles-
erol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP)
evels and might be related to pleiotropic effects of statins. This
eport is similar to the original PROVE IT–TIMI 22 (Pravastatin
r Atorvastatin Evaluation and Infection Therapy–Thrombolysis
n Myocardial Infarction 22) results and raises 3 additional
uestions of clinical importance. First, was the MACE benefit
rimarily in favor of carriers of the KIF6 polymorphism? Second,
as the time to benefit shorter in carriers of the KIF6 polymor-
hism? And third, why were differences in LDL-C and hs-CRP
evels not associated with clinical outcome?
The event rate for the primary composite end point in the
ibson analysis was 21.5% in the atorvastatin 80-mg/day group,
ompared with 26.5% in the pravastatin 40-mg/day group for a
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March 23, 2010:1278–82.0% absolute risk reduction (1). In a genetic substudy of PROVE
T–TIMI 22, only carriers of the KIF6 polymorphism revealed a
ignificant reduction in clinical events when treated with atorva-
tatin (16.1%), compared with the group randomized to pravasta-
in (26.0%), for an absolute risk reduction of 10.0%. In the
on-KIF6 carrier group, the reduction in clinical events did not
iffer between those treated with pravastatin and those treated
ith atorvastatin (2). Thus, genetic analysis identified a subgroup
hat derived the majority of clinical event reductions, and knowl-
dge regarding such an assessment in the Gibson et al. (1) analysis
ight be of clinical relevance.
Second, the original PROVE IT–TIMI 22 report indicated a
ifference in event reduction that became significant at approxi-
ately 180 days. However, the KIF6 genetic substudy revealed a
tatistically significant reduction in events at 30 days and beyond in
nly the KIF6 carrier subgroup and not in the noncarrier subgroup.
arly benefit of statin therapy could be particularly crucial in the
etting of PCI. Statins might potentially improve plaque stability,
mong their other pleiotropic effects, and this would be most
mportant immediately after the intervention.
Third, in the PROVE IT–TIMI 22 genetic substudy, the
edian on-trial LDL-C reduction did not differ between KIF6
arriers and noncarriers. Similar to that seen in the Gibson et al.
1) report, the clinical event benefit in the genetic substudy is
ndependent of LDL-C and hs-CRP level and change during the
rial. This supports their suggestion that a pleiotropic effect is
esponsible for the reduction in MACE, but this effect might be
ost powerful in KIF6 carriers.
In conclusion, the data brought forth by Gibson et al. (1), in
egard to intensive versus moderate statin treatment in acute
oronary syndrome patients requiring PCI, highlight the potential
mportance of the pleiotropic effects of statins. Kinesin proteins
ave a role in intracellular transport and might contribute to these
leiotropic effects (3–6). Genetic polymorphisms such as KIF6ight play a role in differentiating subgroups that respond differ-
ntly to statin therapy.
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